K Hewett

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. doi request reprint Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder
    K Hewett
    GlaxoSmithKline, Harlow, UK
    J Psychopharmacol 24:521-9. 2010
  2. doi request reprint Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR
    Karen Hewett
    GlaxoSmithKline, Pharmaceuticals, New Frontiers Science Park, Harlow, UK
    J Psychopharmacol 24:1209-16. 2010
  3. doi request reprint Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR
    K Hewett
    GlaxoSmithKline, New Frontier Science Park, Harlow, UK
    J Psychopharmacol 23:531-8. 2009

Detail Information

Publications3

  1. doi request reprint Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder
    K Hewett
    GlaxoSmithKline, Harlow, UK
    J Psychopharmacol 24:521-9. 2010
    ..Adverse events were generally mild to moderate and similar between treatment groups. This study demonstrated that the extended-release bupropion is an effective, well-tolerated treatment for major depression in the elderly...
  2. doi request reprint Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR
    Karen Hewett
    GlaxoSmithKline, Pharmaceuticals, New Frontiers Science Park, Harlow, UK
    J Psychopharmacol 24:1209-16. 2010
    ..Rates of dry mouth, insomnia and hyperhidrosis were elevated in the bupropion XR group, consistent with its catecholaminergic mechanism...
  3. doi request reprint Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR
    K Hewett
    GlaxoSmithKline, New Frontier Science Park, Harlow, UK
    J Psychopharmacol 23:531-8. 2009
    ..In this double-blind, placebo-controlled trial, bupropion XR at doses up to 300 mg/day and venlafaxine XR at doses up to 150 mg/day demonstrated comparable antidepressant efficacy...